Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > OT: Details behind $5.7B Danaher acquisition of Abcam

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Oct 11, 2023 12:03pm

259 Views

Post# 35678839

OT: Details behind $5.7B Danaher acquisition of Abcam

UK-based Abcam revealed more details behind its $5.7 billion acquisition by Danaher, including the dozens of potential buyers the company engaged with as well as internal and external turmoil with Abcam’s founder and former CEO Jonathan Milner over the performance of the company, the makeup of the board and the deal with Danaher.

https://otp.investis.com/clients/uk/abcamplc2/sec/sec-show.aspx?Type=html&FilingId=16974085&CIK=0001492074&Index=10000#d878585dex991_htm

<< Previous

Bullboard Posts

Next >>

AI companies to invest in